US pharma giant Pfizer has stressed that its new logo (pictured above) represents more than just a change in artwork.
Chairman and chief executive Albert Bourla has said that the 171-year-old company has arrived at a new era of “extraordinary focus on science and dedication to patients.”
“Pfizer is no longer in the business of just treating diseases — we're curing and preventing them,” Mr Bourla said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze